BHC Stock Performance, Insider Transaction and News

BHC - Bausch Health Companies Inc.

Market Cap	3.39B	P/E	-	EPS this Y	12.60%	Ern Qtrly Grth	-
Income	-592M	Forward P/E	2.52	EPS next Y	6.40%	50D Avg Chg	13.00%
Sales	8.76B	PEG	0.84	EPS past 5Y	-4.46%	200D Avg Chg	22.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	2.60%	52W High Chg	-9.00%
Recommedations	2.90	Quick Ratio	0.69	Shares Outstanding	366.67M	52W Low Chg	88.00%
Insider Own	0.91%	ROA	3.82%	Shares Float	303.99M	Beta	0.86
Inst Own	79.64%	ROE	-686.52%	Shares Shorted/Prior	20.71M/23.78M	Price	9.33
Gross Margin	70.78%	Profit Margin	-6.76%	Avg. Volume	3,585,993	Target Price	10.17
Oper. Margin	21.06%	Earnings Date	May 2	Volume	2,346,502	Change	-1.48%

Healthcare | Drug Manufacturers - Specialty & Generic | Canada

About Bausch Health Companies Inc.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc. News

04/25/24	Earnings Preview: Alignment Healthcare (ALHC) Q1 Earnings Expected to Decline
04/24/24	Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
04/23/24	Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says
04/20/24	10 Best Healthcare Stocks to Buy Under $20
04/11/24	Bausch Health to Announce First-Quarter 2024 Results on May 2
04/11/24	Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
04/11/24	Bausch wins US appeal to block Alvogen generic of diarrhea drug
04/11/24	Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
04/11/24	Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
04/08/24	CANADA STOCKS-TSX ends flat as gold stocks drop, mood cautious ahead of rate decision
04/08/24	Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
04/08/24	BLCO vs. AVTR: Which Stock Is the Better Value Option?
04/05/24	Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
04/03/24	/C O R R E C T I O N from Source -- Canadian Investment Regulatory Organization (CIRO) - Halts/Resumptions/
04/03/24	Here's Why Bausch Health (BHC) is a Strong Momentum Stock
04/03/24	Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
04/02/24	Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
04/01/24	Breakeven Is Near for Bausch Health Companies Inc. (NYSE:BHC)
03/28/24	The Enduring Losses Incurred by Carl Icahn’s 10 Activist Targets over the Long Term
03/28/24	Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?

BHC Chatroom

Rpate Posted - 7 hours ago

$BHC S&P Global ratings upgrades credit rating of BHC on 22/4/2024 Moody's investor service revised outlook on BHC to stable on 23/4/2024

Canuck1867 Posted - 2 days ago

$BHC The vol tells me that the negative conviction is awfully weak and that the Longs have their position and are happy with it. All that's left is to find out who's right....

Stocksrunner Posted - 3 days ago

🎯 Target Price Updates: $BHC RBC cuts target for Bausch Health shares due to Q1 results and BauschLomb spin-off. $BOWL Stifel lowers Bowlero stock target while maintaining buy rating. $GEVO maintains buy rating despite target price cut on strategic and financial update. $DGX sees target raised following a strong quarter. $DPZ anticipated to reveal Q1 results on April 29. Analysts suggest stock is undervalued. 🍕 https://stocksrunner.com/target

DimaZdr Posted - 3 days ago

$BHC

DimaZdr Posted - 3 days ago

$BHC i guess MM ary trying to butn 10$ May calls

metz57 Posted - 3 days ago

$BHC I think I recall the RBC guy missing revenue with the same analysis. Quite the insights from a high paid analyst. The Company could or could not do the spin. I think this Board provides more insights than RBC has: RBC estimates Q1/24 revenue of $2.13 billion (FactSet cons. $2.15 billion) and adj. EBITDA of $682 million (FactSet cons. $730 million). Analyst Douglas Miehm expects the focus to be on a potential BLCO distribution to BHC shareholders and the factors influencing such a decision. (in US$). "We believe that following the Appellate Court's ruling, BHC stands in a stronger position to move forward with a potential BLCO distribution. However, Amneal's ANDA submission has likely added additional complexity to the situation," he said. Target lowered by US$1, to US$11, maintain Sector Perform.

marcbirn Posted - 3 days ago

$BHC RBC Trims Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating 6:45 AM 04/23/2024

SellSalix Posted - 4 days ago

@BuytheCalls nobody will ever buy $BHC . There are just too many unknowns specific to Xifaxan and there’s simply too much debt. Now, a buyer could come in and make an offer for $BLCO . I would take anything over $27 and call it a day.

metz57 Posted - 4 days ago

$BHC This may be part of the problem today (even though BLCO is up slightly), RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1

BuytheCalls Posted - 4 days ago

$BHC management must either sell BHC or sell BLCO.

GreedyBunny Posted - 4 days ago

$BHC As discussed Appio didn’t have to be negative. He’s either an idiot or maybe he’s trying to keep the bonds discounted for as long as possible. Which? 🤔

metz57 Posted - 4 days ago

$BHC I realize the annual reports are written for lawyers and not investors but the BHC report on the spin was painful as it was so dysfunctional. Basically, we are hosed if we spin and hosed if we don't. That was the brilliant management discussion. If Appio comes out again and say the distribution is our preferred course but no decisions have been made time to either sell or just write calls as the stock is not going higher. Someone over the last year has been making a lot of money selling the calls every month.

DimaZdr Posted - 1 week ago

$BHC when are ruling results coming out?

mail717c Posted - 1 week ago

$BHC Happy Friday suckers. hope this comes up in a long run.

89quattro Posted - 1 week ago

$BHC Happy Friday

algomezus Posted - 1 week ago

$BHC one-day gang one stinking day we will be rewarded.....

Rpate Posted - 1 week ago

$BHC Strong grip of bull in BHC.

89quattro Posted - 1 week ago

$BHC bring back Joe Papa, we need some of his patented Opportunity of a Lifetime energy. hahahaha….

ebu Posted - 1 week ago

$BHC now what?

RickyVonOatmeal Posted - 1 week ago

$BHC Imagine how bad it would have been if they actually LOST the Norwich case. OMG, what a dud.

momos Posted - 1 week ago

$BHC lost so much value with the Norwich lawsuit. Continues to lose value with a lawsuit win. Moral of the story, this stock only loses value.

SellSalix Posted - 1 week ago

$BHC Hi, need u guys to confirm my understanding of the facts: 1) Norwich cannot go live until 2029; 2) Norwich can, however, file a new ADNA (albeit skinny label) with the FDA, but $BHC will sue and a 30 month stay will be issued; 3) Amneal, at the earliest can only live with its generic on/around October of 2025, or earlier if judge orders otherwise. Question: As a result of BHC losing on its appeal to overturn the patent rulings related to IBD-S, are the patents (specific to IBD-S) invalid then? In other words, can a generic go live with a skinny label or do the HE patents (which were affirmed as valid) prevent any company going live with a generic version of Xifaxan?

CindyH0o Posted - 1 week ago

$BHC XBI Was 103 in Feb. Now 87 IBB was 140 in Feb. Now 129. Drug and bio have done poorly in the past 2 months. $BLCO. They need to reverse..

Vantor Posted - 1 week ago

@GreedyBunny I think $BLCO is just following market trends in regards to riskier smaller cap stocks. They were performing surprisingly well and now that bullish trend has been put on pause or even reversed itself, especially since investor sentiment towards interest rate increases has also reversed itself. Morningstar has listed $BLCO a buy, saying its trading at nearly half its fair value; my understanding is they dropped coverage of $BHC because of all the legal uncertainty. If $BLCO is a buy, though, how is $BHC not?

BuyTheCrisis_ Posted - 2 weeks ago

$BHC never ending story...lol

truckersam Posted - 2 weeks ago

$BHC would have been better investing in Hookers

btradingwarehouse Posted - 2 weeks ago

$BHC ...2BULLS... ... if we get "hook" pattern... ... ... ... ... ..perfect !!! if we do not get it but (> $8.54)... ... ...good !!! ... ... enjoy weekend relax

jrshoops Posted - 2 weeks ago

$BHC guess I shouldn't have added yesterday after we protected our cash cow until 2028 😥😂😥ughhhh

CindyH0o Posted - 2 weeks ago

$BHC for April 19, 49k calls between 10-11 were bought. Nearly 5 million shares. Most likely worthless. Algo is turned on and beautifully doing as expected. If market turns green, then so this. I did sell puts yesterday but red in here seems worthless. Seem next catalyst is May 2.

nabisko7 Posted - 2 weeks ago

$BHC they need to release scholarships

Analyst Ratings

RBC Capital	Sector Perform	Apr 23, 24
RBC Capital	Sector Perform	Apr 12, 24
RBC Capital	Sector Perform	Apr 5, 24
RBC Capital	Sector Perform	Feb 23, 24
Jefferies	Buy	Sep 20, 23
TD Cowen	Market Perform	Jun 16, 23
Jefferies	Buy	May 22, 23
RBC Capital	Sector Perform	May 5, 23
Piper Sandler	Neutral	Sep 9, 22

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Carson Seana	EVP, General Counsel EVP, General Counsel	Nov 03	Sell	7.61	43	327	384,836	11/06/23
Carson Seana	EVP, General Counsel EVP, General Counsel	Feb 27	Sell	9.32	292	2,721	359,185	03/01/23
Spurr Robert	U.S. President-Pharm.. U.S. President-Pharma Business	Apr 14	Sell	22.19	1,595	35,393	90,506	04/15/22
Gordon Joseph F	Pres&Co-Head Bausch&.. Pres&Co-Head Bausch&Lomb/Int'l	Mar 08	Sell	21.76	3,889	84,625	93,139	03/10/22
Gordon Joseph F	Pres&Co-Head Bausch&.. Pres&Co-Head Bausch&Lomb/Int'l	Feb 26	Sell	23.82	6,338	150,971	112,179	03/02/22
Spurr Robert	U.S. President-Pharm.. U.S. President-Pharma Business	Jan 18	Sell	26.63	3,251	86,574	63,550	01/20/22
Miller Steven D	Director Director	Nov 30	Buy	24.2	60,000	1,452,000	10,000	12/02/21
Humphries William D.	President, Ortho-Der.. President, Ortho-Dermatologics	Dec 08	Option	14.38	114,055	1,640,111	349,090	12/08/20
Humphries William D.	President, Ortho-Der.. President, Ortho-Dermatologics	Dec 08	Sell	19.87	114,055	2,266,273	235,035	12/08/20